PR Newswire
MENLO PARK, Calif., Dec. 20, 2018
MENLO PARK, Calif., Dec. 20, 2018 /PRNewswire/
-- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical
dermatology products, received a notice on December 17, 2018 from the NYSE American LLC (the "NYSE
American") that the Company is not in compliance with the stockholders' equity requirements set forth in Section 1003(a)(i) and
Section 1003(a)(ii) of the NYSE American Company Guide. The Company reported stockholders' equity of $0.6 million as
of October 31, 2018 and net losses in its five most recent fiscal years ended January 31, 2018. The
continued listing standards require listed companies to maintain stockholders' equity of $2.0 million or more if they
have reported losses from continuing operations and/or net losses in their three most recent fiscal years. NYSE Regulation
has reviewed the Company's compliance plan and has granted a plan period through September 24, 2019.
The Company's common stock will continue to be listed and traded on NYSE American during the cure period, subject to the
Company's compliance with NYSE American's other applicable continued listing standards. The letter does not affect the company's
business operations or its Securities and Exchange Commission reporting requirements.
About BioPharmX® Corporation
BioPharmX Corporation (NYSE American: BPMX) is a specialty pharmaceutical company developing prescription products
through proprietary platform technologies for dermatology indications. To learn more about BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statement
The information in this press release contains forward-looking statements and information within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are
subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the
company's expectations, plans, intentions, and strategies, including, but not limited to, our ability to regain compliance with
the continued listing standards of the NYSE American. Additional risks are set forth in our filings with the Securities and
Exchange Commission, including those described in the company's Quarterly Report on Form 10-Q for the most recent fiscal quarter.
The forward-looking statements included in this news release are made only as of the date hereof, and the company undertakes no
obligation to publicly update such statements. BioPharmX is a registered trademark of BioPharmX, Inc.
View original content to download multimedia:http://www.prnewswire.com/news-releases/biopharmx-receives-notice-of-noncompliance-from-nyse-american-300769651.html
SOURCE BioPharmX Corporation